Beryl Drugs Q4 Results
- BSE: 524606
- NSE: -
- ISIN: INE415H01017
- Sector: Biotechnology & Drugs
BSE
23.50
0.48 (2.09%)
0.48 (2.09%)Volume418.00
Updated: Mon 15 Jun, 2026 | 15:18:51
NSE
This stock is not traded on NSE
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
- Total Income₹5.13 Cr.(29.08%)
- Operating Profit₹0.60 Cr.(NA%)
- Profit After Tax₹0.56 Cr.(270.31%)
- Operating Margin11.68%(NA%)
Note: Comparison is on YoY basis
Quarterly - Beryl Drugs Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 26 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 4.53 | 4.37 | 3.75% | 3.50 | -10.10% |
| Depreciation/ Amortization | 0.40 | 0.32 | 26.48% | 0.32 | 27.20% |
| Operating Income | 0.60 | -0.59 | 0.00% | -0.52 | 0.00% |
| Net Income | 0.56 | -0.17 | 0.00% | -0.35 | 270.31% |
| Net Income Before Taxes | 0.87 | -0.61 | 0.00% | -0.42 | 750.49% |
| Other Operating Expenses Total | 0.38 | 1.22 | -69.32% | -0.33 | -71.38% |
| Total Revenue | 5.13 | 3.78 | 35.81% | 2.98 | 29.08% |
| Selling/ General/ Admin Expenses Total | 0.63 | 0.79 | -20.29% | 0.49 | 5.82% |
| Diluted Normalized EPS | 1.11 | -0.33 | 0.00% | -0.68 | 268.31% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.